HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Kalinsky Discusses the Evolution of HER2+ Breast Cancer

September 5th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.

Tolaney Discusses Developments Across Breast Cancer Subtypes

August 28th 2018

Sara M. Tolaney, MD, MPH, discusses developments in the treatment paradigms for patients with HR-positive or HER2-positive breast cancer.

Dr. Sparano Discusses Unmet Needs in Metastatic Breast Cancer

August 27th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast Cancer

August 22nd 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.

New Recommendations Improve Accuracy of HER2 Status Designation

August 17th 2018

The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.

CNS Metastases Remain Unmet Need in HER2+ Breast Cancer

August 14th 2018

Kevin Kalinsky, MD, discusses the current treatment landscape of metastatic HER2-positive breast cancer, the potential for immunotherapy, and what is on the horizon for patients in this population who develop brain metastases.

Dr. Hurvitz on How to Navigate HER2-Targeted Therapy in Breast Cancer

August 10th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, advises how to navigate therapy for patients with HER2-positive breast cancer.

The State of HER2+ Breast Cancer in the Curative Setting

August 10th 2018

Rashmi K. Murthy, MD, discusses selecting therapy for patients with HER2-positive breast cancer in the curative setting.

Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer

August 8th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast Cancer

August 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Hurvitz Highlights Advances in HER2+ Breast Cancer Treatment

August 6th 2018

Sara A. Hurvitz, MD, discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.

Yardley Recaps Breast Cancer Data From ASCO 2018

August 2nd 2018

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Dr. Murthy on Future of Tucatinib in HER2+ Breast Cancer

August 1st 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of tucatinib in HER2-positive breast cancer.

Dr. Murthy on Caveats of the PERSEPHONE Trial in Breast Cancer

July 26th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses caveats of the PERSEPHONE trial.

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

July 19th 2018

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

Dr. Ali on Choosing Neratinib in HER2+ Breast Cancer

July 12th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Iwata Discusses DS-8201a in HER2+ Breast Cancer

July 10th 2018

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses DS-8201a in HER2-positive breast cancer.

Esteva Recaps Advances in HER2-Targeted Therapy in Breast Cancer

July 6th 2018

Francisco J. Esteva, MD, PhD, discusses recent advances and clinical findings with HER2-targeted therapies across the neoadjuvant, adjuvant, and metastatic settings.

Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer

July 4th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

De-escalated, Chemo-Free Neoadjuvant Path Viable in HER2+/HR+ Breast Cancer

July 3rd 2018

A de-escalated, chemotherapy-free neoadjuvant regimen of letrozole plus dual HER2 blockade showed promise in patients with HER2+/HR+ breast cancer who first achieved a molecular response to 2 weeks of letrozole.